Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTO-104 Open-Label Extension in Meniere's Disease
NCT02706730Phase 3Terminated
- Sponsor
- Otonomy, Inc.
- Start
- Feb 2016
- Primary completion
- Sep 2017
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Otividex in Meniere's disease (MD), sponsored by Otonomy, Inc. Primary endpoint: Otoscopic Examination - Tympanic Membrane Perforation at Week 24 (Month 6). Started Feb 2016; status: terminated.
02
Drugs
Otividex
03
Conditions
Meniere's disease (MD)
Beyond the preview
Go deeper on NCT02706730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02706730.